analytica’s Post

Researchers at ETH created a cost-effective device for accurate blood measurements using a suction cup. It can also diagnose malaria, usable by non-medical individuals. 🩸 In brief ◼️ A new device for taking blood samples uses microneedles and a suction cup instead of a large needle. People with a phobia of needles stand to benefit. ◼️ More blood can be obtained than with the classic finger prick, making diagnostic measurements more reliable. ◼️ Because the device can be produced at low cost, it is also suitable for developing countries. Article: Fabio Bergamin Image: Colourbox Mentioned: Jean-Christophe Leroux, Nicole Zoratto, David Klein Cerrejon, Fondation Botnar, Basel Research Centre for Child Health #MalariaDiagnose #BloodMeasurements #Microneedle

#Measles and #rubella present similar symptoms of acute fever and rash, posing serious health risks to children and teenagers. Early and accurate detection is crucial for effective treatment. #BioPerfectus offers the Measles and Rubella Viruses Real-Time PCR Kit to aid in accurate diagnosis.   Micron Biomedical, based in Georgia, #USA, recognized as a category leader, is building a mass production facility for needle-free pharmaceuticals. As a clinical-stage life science company committed to expanding access to vaccines and therapeutics globally.   Yasmine Gomaa, Principal Scientist at Micron Biomedical, shares her insight: "𝐁𝐢𝐨𝐏𝐞𝐫𝐟𝐞𝐜𝐭𝐮𝐬 𝐌𝐞𝐚𝐬𝐥𝐞𝐬 𝐚𝐧𝐝 𝐑𝐮𝐛𝐞𝐥𝐥𝐚 𝐕𝐢𝐫𝐮𝐬𝐞𝐬 𝐑𝐞𝐚𝐥-𝐓𝐢𝐦𝐞 𝐏𝐂𝐑 𝐊𝐢𝐭 𝐰𝐚𝐬 𝐬𝐚𝐯𝐢𝐧𝐠 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐭𝐢𝐦𝐞 𝐨𝐧 𝐫𝐮𝐧𝐧𝐢𝐧𝐠 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞𝐱 𝐏𝐂𝐑 𝐭𝐞𝐬𝐭𝐬 𝐨𝐧 𝐛𝐢𝐯𝐚𝐥𝐞𝐧𝐭 𝐬𝐚𝐦𝐩𝐥𝐞𝐬 𝐰𝐢𝐭𝐡 𝐬𝐢𝐦𝐢𝐥𝐚𝐫 𝐚𝐜𝐜𝐮𝐫𝐚𝐜𝐲 𝐭𝐨 𝐭𝐡𝐞 𝐂𝐪 𝐯𝐚𝐥𝐮𝐞𝐬 𝐟𝐨𝐫 𝐦𝐨𝐧𝐨𝐩𝐥𝐞𝐱. 𝐓𝐡𝐚𝐭'𝐬 𝐞𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐭. 𝐈 𝐰𝐢𝐥𝐥 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞 𝐭𝐨 𝐮𝐬𝐞 𝐨𝐭𝐡𝐞𝐫 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬 𝐟𝐫𝐨𝐦 𝐁𝐢𝐨𝐏𝐞𝐫𝐟𝐞𝐜𝐭𝐮𝐬."   Together, we unite in the fight against measles and rubella, striving for improved health outcomes worldwide.   🔬Discover more about our products: https://lnkd.in/eT-j6q_j #BioPerfectus #IVD #Healthcare #Diagnostics #PCR #MolecularDiagnostic

The typical challenges surrounding all clinical trials – too slow, expensive, and unpredictable – are amplified for the development of orphan drugs. This article breaks down 5 key considerations for sponsors when designing rare disease clinical trials.

The typical challenges surrounding all clinical trials – too slow, expensive, and unpredictable – are amplified for the development of orphan drugs. This article breaks down 5 key considerations for sponsors when designing rare disease clinical trials.

CEO Piotr Trzonkowski will join the ranks of other leading investigators and clinicians at the 6h International Sam Strober Workshop on Clinical Immune Tolerance at the prestigious University of Oxford. Prof. Trzonkowski will be the first speaker on Tuesday, 26 March, to discuss PolTREG’s experience with diabetes. Did you know that PolTREG has administered Treg cells to more than 100 autoimmune patients in its 17-year history? These therapies are not yet on the market, but patients may receive them under a hospital exemption or in clinical trials. Learn more: https://lnkd.in/d6QNequ2 #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #investing #diabetes

The typical challenges surrounding all clinical trials – too slow, expensive, and unpredictable – are amplified for the development of orphan drugs. This article breaks down 5 key considerations for sponsors when designing rare disease clinical trials.

The typical challenges surrounding all clinical trials – too slow, expensive, and unpredictable – are amplified for the development of orphan drugs. This article breaks down 5 key considerations for sponsors when designing rare disease clinical trials.

The typical challenges surrounding all clinical trials – too slow, expensive, and unpredictable – are amplified for the development of orphan drugs. This article breaks down 5 key considerations for sponsors when designing rare disease clinical trials.

Antiphospholipid antibodies (APLA) are a heterogeneous group of antibodies against different phospholipids, including anti-phosphatidylserine, anti-phosphatidylinositol, anti-phosphatidylglycerol, anti-cardiolipin, anti-phosphatidylethanolamine, or anti-phosphatidic acid. In this paper, the authors aimed to assess the relationship between positivity of different APLAs, including criteria and non-criteria APLAs, during the acute phase of disease with thrombosis, inflammation, or clinical parameters related to the severity of COVID-19. 📝 Thrombosis and Hyperinflammation in COVID-19 Acute Phase Are Related to Anti-Phosphatidylserine and Anti-Phosphatidylinositol Antibody Positivity — Alijotas-Reig, et al. Full text is available 👇 https://lnkd.in/dSg5FDnc #medicine #health #research #science

The typical challenges surrounding all clinical trials – too slow, expensive, and unpredictable – are amplified for the development of orphan drugs. This article breaks down 5 key considerations for sponsors when designing rare disease clinical trials.